Solid Biosciences Inc. (SLDB) stock
Close on Nov 11, 2026Market cap $814.91MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $814.91M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.38
- Dividend yield
- –
- Free cash flow yield
- -19.32%
Fundamentals
- EPS, diluted
- -$1.99
- Free cash flow
- -$200.30M
- Book value per share
- $2.27
- Diluted shares
- 151M
Trading
- Previous close
- $7.17
- Open
- $7.26
- Day's range
- $7.18 – $7.86
- Volume
- 1,957,995
- Average volume (20 days)
- 1,386,398
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.88
- 52-week range
- $4.05 – $11.45
- RSI (14 days)
- 62.2
- Volatility (1 year)
- 77.0%
- Relative volume
- 1.66×
- WACC
- 14.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SLDB | S&P 500 | Difference | SLDB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +10.6% | -2.4% | +13.0 pts | ||
| 3 months | -14.1% | -1.2% | −13.0 pts | ||
| Year to date | +34.8% | +12.3% | +22.5 pts | ||
| 1 year | +67.8% | +12.4% | +55.3 pts | ||
| 3 years | +243.9% | +78.8% | +165.1 pts | +50.9% | +21.4% |
| 5 years | -76.5% | +75.2% | −151.7 pts | -25.2% | +11.9% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Solid Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Results
- Results
About Solid Biosciences
Biological Products, (No Diagnostic Substances)
Solid Biosciences Inc. is a life sciences company that develops gene therapies for rare neuromuscular and cardiac diseases. Its research and development efforts focus on gene transfer candidates designed to deliver functional transgenes to treat conditions caused by mutated genes. The company's pipeline includes investigational therapies such as SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for dilated cardiomyopathy. Because its pipeline remains in development, the company does not currently sell commercial products, and its target end-users are patients suffering from these conditions.
Company profile, executives and historySolid Biosciences stock: common questions
What is Solid Biosciences's stock price?
SLDB closed at $7.60 on Nov 11, 2026, up 6.00% on the day. Over the past 52 weeks it traded between $4.05 and $11.45.
What is Solid Biosciences's market cap?
Solid Biosciences was worth $814.91M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SLDB's P/E ratio?
Solid Biosciences lost money over fiscal 2025 (diluted EPS -$1.99), so it has no meaningful P/E ratio.
Does Solid Biosciences pay a dividend?
No. Solid Biosciences has not paid a cash dividend over the last twelve months.
How has SLDB stock performed over the past year?
Including dividends, SLDB returned +67.8% over the past year, against +12.4% for the S&P 500.
How many SLDB shares are sold short?
13M shares were sold short at the latest FINRA report, 16.93% of the float, or 10.7 days of average trading volume.
Who are Solid Biosciences's competitors?
Companies most similar to Solid Biosciences by business, industry and size include LXEO, RLAY, TNYA, SGMOQ, PRME.
See a number that looks wrong?